Parkinsons Disease Biomarkers Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Parkinson’s Disease Biomarkers Market 

5.1. COVID-19 Landscape: Parkinson’s Disease Biomarkers Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Parkinson’s Disease Biomarkers Market, By Biomarker Type

8.1. Parkinson’s Disease Biomarkers Market, by Biomarker Type

8.1.1. Molecular Biomarkers

8.1.1.1. Market Revenue and Forecast

8.1.2. Imaging Biomarkers

8.1.2.1. Market Revenue and Forecast

8.1.3. Genetic Biomarkers

8.1.3.1. Market Revenue and Forecast

8.1.4. Biochemical Biomarkers

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Parkinson’s Disease Biomarkers Market, By Technology

9.1. Parkinson’s Disease Biomarkers Market, by Technology

9.1.1. Immunoassays

9.1.1.1. Market Revenue and Forecast

9.1.2. Molecular Diagnostics

9.1.2.1. Market Revenue and Forecast

9.1.3. Proteomics

9.1.3.1. Market Revenue and Forecast

9.1.4. Obstetrics

9.1.4.1. Market Revenue and Forecast

9.1.5. Genomics

9.1.5.1. Market Revenue and Forecast

9.1.6. Neuroimaging Technologies

9.1.6.1. Market Revenue and Forecast

9.1.7. AI-based Biomarker Analysis

9.1.7.1. Market Revenue and Forecast

Chapter 10. Global Parkinson’s Disease Biomarkers Market, By Application 

10.1. Parkinson’s Disease Biomarkers Market, by Application

10.1.1. Early Diagnosis

10.1.1.1. Market Revenue and Forecast

10.1.2. Disease Progression Monitoring

10.1.2.1. Market Revenue and Forecast

10.1.3. Drug Discovery & Development

10.1.3.1. Market Revenue and Forecast

10.1.4. Personalized Medicine

10.1.4.1. Market Revenue and Forecast

10.1.5. Clinical Research

10.1.5.1. Market Revenue and Forecast

Chapter 11. Global Parkinson’s Disease Biomarkers Market, By End-Use 

11.1. Parkinson’s Disease Biomarkers Market, by End-Use

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast

11.1.2. Diagnostic Laboratories

11.1.2.1. Market Revenue and Forecast

11.1.3. Academic & Research Institutes

11.1.3.1. Market Revenue and Forecast

11.1.4. Specialty Neurology Clinics

11.1.4.1. Market Revenue and Forecast

11.1.5. Pharmaceutical & Biotechnology Companies

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global Parkinson’s Disease Biomarkers Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Biomarker Type

12.1.2. Market Revenue and Forecast, by Technology

12.1.3. Market Revenue and Forecast, by Application

12.1.4. Market Revenue and Forecast, by End-Use

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Biomarker Type

12.1.5.2. Market Revenue and Forecast, by Technology

12.1.5.3. Market Revenue and Forecast, by Application

12.1.5.4. Market Revenue and Forecast, by End-Use

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Biomarker Type

12.1.6.2. Market Revenue and Forecast, by Technology

12.1.6.3. Market Revenue and Forecast, by Application

12.1.6.4. Market Revenue and Forecast, by End-Use

12.2. Europe

12.2.1. Market Revenue and Forecast, by Biomarker Type

12.2.2. Market Revenue and Forecast, by Technology

12.2.3. Market Revenue and Forecast, by Application

12.2.4. Market Revenue and Forecast, by End-Use

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Biomarker Type

12.2.5.2. Market Revenue and Forecast, by Technology

12.2.5.3. Market Revenue and Forecast, by Application

12.2.5.4. Market Revenue and Forecast, by End-Use

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Biomarker Type

12.2.6.2. Market Revenue and Forecast, by Technology

12.2.6.3. Market Revenue and Forecast, by Application

12.2.6.4. Market Revenue and Forecast, by End-Use

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Biomarker Type

12.2.7.2. Market Revenue and Forecast, by Technology

12.2.7.3. Market Revenue and Forecast, by Application

12.2.7.4. Market Revenue and Forecast, by End-Use

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Biomarker Type

12.2.8.2. Market Revenue and Forecast, by Technology

12.2.8.3. Market Revenue and Forecast, by Application

12.2.8.4. Market Revenue and Forecast, by End-Use

12.3. APAC

12.3.1. Market Revenue and Forecast, by Biomarker Type

12.3.2. Market Revenue and Forecast, by Technology

12.3.3. Market Revenue and Forecast, by Application

12.3.4. Market Revenue and Forecast, by End-Use

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Biomarker Type

12.3.5.2. Market Revenue and Forecast, by Technology

12.3.5.3. Market Revenue and Forecast, by Application

12.3.5.4. Market Revenue and Forecast, by End-Use

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Biomarker Type

12.3.6.2. Market Revenue and Forecast, by Technology

12.3.6.3. Market Revenue and Forecast, by Application

12.3.6.4. Market Revenue and Forecast, by End-Use

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Biomarker Type

12.3.7.2. Market Revenue and Forecast, by Technology

12.3.7.3. Market Revenue and Forecast, by Application

12.3.7.4. Market Revenue and Forecast, by End-Use

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Biomarker Type

12.3.8.2. Market Revenue and Forecast, by Technology

12.3.8.3. Market Revenue and Forecast, by Application

12.3.8.4. Market Revenue and Forecast, by End-Use

12.4. MEA

12.4.1. Market Revenue and Forecast, by Biomarker Type

12.4.2. Market Revenue and Forecast, by Technology

12.4.3. Market Revenue and Forecast, by Application

12.4.4. Market Revenue and Forecast, by End-Use

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Biomarker Type

12.4.5.2. Market Revenue and Forecast, by Technology

12.4.5.3. Market Revenue and Forecast, by Application

12.4.5.4. Market Revenue and Forecast, by End-Use

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Biomarker Type

12.4.6.2. Market Revenue and Forecast, by Technology

12.4.6.3. Market Revenue and Forecast, by Application

12.4.6.4. Market Revenue and Forecast, by End-Use

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Biomarker Type

12.4.7.2. Market Revenue and Forecast, by Technology

12.4.7.3. Market Revenue and Forecast, by Application

12.4.7.4. Market Revenue and Forecast, by End-Use

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Biomarker Type

12.4.8.2. Market Revenue and Forecast, by Technology

12.4.8.3. Market Revenue and Forecast, by Application

12.4.8.4. Market Revenue and Forecast, by End-Use

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Biomarker Type

12.5.2. Market Revenue and Forecast, by Technology

12.5.3. Market Revenue and Forecast, by Application

12.5.4. Market Revenue and Forecast, by End-Use

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Biomarker Type

12.5.5.2. Market Revenue and Forecast, by Technology

12.5.5.3. Market Revenue and Forecast, by Application

12.5.5.4. Market Revenue and Forecast, by End-Use

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Biomarker Type

12.5.6.2. Market Revenue and Forecast, by Technology

12.5.6.3. Market Revenue and Forecast, by Application

12.5.6.4. Market Revenue and Forecast, by End-Use

Chapter 13. Company Profiles

13.1. F. Hoffmann-La Roche Ltd.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bio-Rad Laboratories

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Thermo Fisher Scientific

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Abbott Laboratories

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Quanterix

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Siemens Healthineers

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. GE HealthCare

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. PerkinElmer

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sysmex Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Biogen Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms